Plus Therapeutics Jumps After FDA Grants Orphan-Drug Status Plus Therapeutics received FDA orphan-drug status on Apr 8, 2026; orphan designation gives 7 years of U.S. exclusivity, changing commercial optionality for PSTV.

Plus Therapeutics Jumps After FDA Grants Orphan-Drug Status: Plus Therapeutics received FDA orphan-drug status on Apr 8, 2026; orphan designation gives 7 years of U.S. exclusivity, changing commercial… 👈 Read full analysis #PlusTherapeutics #OrphanDrug #FDAApproval #HealthcareInvestment #PharmaNews